KRAS and lung carcinoma: Importantly, BCL6 depletion impeded lung tumorigenesis in a genetically engineered KrasG12D-driven mouse model, and pharmacological inhibition of BCL6 consistently reduced the growth of KRAS-mutant lung cancer cells and prolonged mouse survival.